

Limits on Medicare's Ability to Control Rising Spending

New England Journal of Medicine

360, 626-633

DOI: [10.1056/nejmhpr0807774](https://doi.org/10.1056/nejmhpr0807774)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Contradictory Actions on Off-Label Use of Prescription Drugs? The FDA and CMS Versus the U.S. Justice Department. <i>Journal of Managed Care Pharmacy</i> , 2009, 15, 161-165.	2.2	5
2	Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics. <i>PLoS ONE</i> , 2009, 4, e7746.	1.1	73
3	Making Longevity in an Aging Society: Linking Ethical Sensibility and Medicare Spending. <i>Medical Anthropology: Cross Cultural Studies in Health and Illness</i> , 2009, 28, 317-325.	0.6	18
4	To Tell or Not to Tell: The Community Wants to Know About Expensive Anticancer Drugs As a Potential Treatment Option. <i>Journal of Clinical Oncology</i> , 2009, 27, 5830-5837.	0.8	24
5	Controlling the cost of innovative cancer therapeutics. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 550-552.	12.5	38
6	Adjuvant Anthracyclines and Taxanes: Quantifying the Costs of Therapeutic Advances in Breast Cancer. <i>Onkologie</i> , 2009, 32, 2-2.	1.1	1
8	Expensive Cancer Drugs: A Comparison between the United States and the United Kingdom. <i>Milbank Quarterly</i> , 2009, 87, 789-819.	2.1	51
9	Challenges and Opportunities for Use of Cost-Effectiveness Analysis. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1161-1163.	3.0	13
10	Value-based insurance design in medicare. <i>Applied Health Economics and Health Policy</i> , 2009, 7, 149-154.	1.0	2
11	State of the Art Management in Spine Oncology. <i>Spine</i> , 2009, 34, S7-S20.	1.0	35
12	Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1625.	3.8	198
14	Pem and the Cost of Multicycle Maintenance. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1111-1112.	0.5	17
15	How might VAâ€œMedicare differences inform the delivery of endâ€œofâ€œlife cancer care?. <i>Cancer</i> , 2010, 116, 3533-3536.	2.0	3
16	Towards patient-based cancer therapeutics. <i>Nature Biotechnology</i> , 2010, 28, 904-906.	9.4	65
17	Targeted cancer therapies. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 427-428.	21.5	160
18	Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support the Rhetoric?. <i>Journal of Clinical Oncology</i> , 2010, 28, 3234-3238.	0.8	74
19	Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?. <i>Clinical Cancer Research</i> , 2010, 16, 5972-5980.	3.2	105
20	Impact of the Cost of Cancer Treatment: An Internet-Based Survey. <i>Journal of Oncology Practice</i> , 2010, 6, 69-73.	2.5	84

#	ARTICLE	IF	CITATIONS
21	Value and Cancer Care: Toward an Equitable Future. <i>Clinical Cancer Research</i> , 2010, 16, 6004-6008.	3.2	36
24	When is Cancer Care Cost-Effective? A Systematic Overview of Cost-Utility Analyses in Oncology. <i>Journal of the National Cancer Institute</i> , 2010, 102, 82-88.	3.0	163
25	Sipuleucel-T immunotherapy for advanced prostate cancer. <i>Community Oncology</i> , 2010, 7, 342-344.	0.2	1
26	The conundrum of sipuleucel-T for prostate cancer. <i>Community Oncology</i> , 2010, 7, 343-344.	0.2	1
27	Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 277-291.	21.5	127
28	Cancer's Next Frontier. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1086.	3.8	136
29	Advances in Cancer Therapeutics and Patient Access to New Drugs. <i>Pharmacoeconomics</i> , 2011, 29, 213-224.	1.7	21
30	Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2006-2014.	1.1	395
31	A Trial-Based Assessment of the Cost-Utility of Bevacizumab and Chemotherapy versus Chemotherapy Alone for Advanced Non-Small Cell Lung Cancer. <i>Value in Health</i> , 2011, 14, 836-845.	0.1	88
32	Pharmacoeconomic analysis of consolidation therapy with pemetrexed after first-line chemotherapy for non-small cell lung cancer. <i>Lung Cancer</i> , 2011, 74, 521-528.	0.9	13
33	Hematopoietic Growth Factors in Oncology. <i>Cancer Treatment and Research</i> , 2011, , .	0.2	5
35	The development of a value based pricing index for new drugs in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2011, 47, 1299-1304.	1.3	7
36	The pharmacoeconomics of spiralling cancer drug costs – Is there a viable solution?. <i>European Journal of Cancer</i> , 2011, 47, 1285-1286.	1.3	2
37	The opportunity cost of cancer care: a statement from NICE. <i>Lancet Oncology</i> , The, 2011, 12, 931-932.	5.1	13
38	Promising therapies, prohibitive costs: a qualitative assessment of the effects of the Medicare Part D doughnut hole on access to costly cancer medications. <i>Community Oncology</i> , 2011, 8, 111-117.	0.2	2
39	Initial Patterns of Care With Oral Targeted Therapies for Patients With Renal Cell Carcinoma. <i>Urology</i> , 2011, 77, 825-830.e1.	0.5	17
40	Counterpoint: Chemosensitivity Assays for Recurrent Ovarian Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 121-124.	2.3	9
41	Off-Label Drug Use and Promotion: Balancing Public Health Goals and Commercial Speech. <i>American Journal of Law and Medicine</i> , 2011, 37, 225-257.	0.5	16

#	ARTICLE	IF	CITATIONS
42	How much is the life of a cancer patient worth? A pharmaco-economic perspective. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 249-256.	0.7	18
43	Medicare, Ethics, and Reflexive Longevity: Governing Time and Treatment in an Aging Society. <i>Medical Anthropology Quarterly</i> , 2011, 25, 209-231.	0.7	24
44	The economic pressures for biosimilar drug use in cancer medicine. <i>Oncologie</i> , 2011, 13, 222-233.	0.2	3
46	How Long and How Well. <i>Medical Decision Making</i> , 2011, 31, 380-385.	1.2	26
47	Big Costs for Little Gain in Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1230-1232.	0.8	28
48	Projections of the Cost of Cancer Care in the United States: 2010-2020. <i>Journal of the National Cancer Institute</i> , 2011, 103, 117-128.	3.0	2,151
49	Circulating Tumor Cells and PET. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1501-1504.	2.8	14
50	Improving Quality and Addressing the Rising Costs of Cancer Care: Two Birds, One Stone. <i>Journal of Oncology Practice</i> , 2011, 7, 402-404.	2.5	2
51	Episode-Based Payment For Cancer Care: A Proposed Pilot For Medicare. <i>Health Affairs</i> , 2011, 30, 500-509.	2.5	51
54	Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 113-119.	0.7	8
55	Racial Variation in the Cost-Effectiveness of Chemotherapy for Prostate Cancer. <i>Journal of Oncology Practice</i> , 2011, 7, e16s-e24s.	2.5	8
56	Bending the Cost Curve in Cancer Care. <i>New England Journal of Medicine</i> , 2011, 364, 2060-2065.	13.9	358
57	The Real Constitutional Problem with the Affordable Care Act. <i>Journal of Health Politics, Policy and Law</i> , 2011, 36, 501-506.	0.9	2
58	Finasteride and Prostate Cancer: A Commentary. <i>Oncologist</i> , 2012, 17, 888-890.	1.9	2
59	International Variability in the Reimbursement of Cancer Drugs by Publically Funded Drug Programs. <i>Current Oncology</i> , 2012, 19, 165-176.	0.9	74
60	A Model to Estimate Human Resource Needs for the Treatment of Outpatients With Cancer. <i>Journal of Oncology Practice</i> , 2012, 8, 13-17.	2.5	13
61	Financial Hardship: A Consequence of Survivorship?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1579-1580.	0.8	17
62	Therapies For Advanced Cancers Pose A Special Challenge For Health Technology Assessment Organizations In Many Countries. <i>Health Affairs</i> , 2012, 31, 700-708.	2.5	28

#	ARTICLE	IF	CITATIONS
63	Valuing end-of-life care in the United States: the case of new cancer drugs. <i>Health Economics, Policy and Law</i> , 2012, 7, 411-430.	1.1	12
64	Cost, Coverage, and Comparative Effectiveness Research: The Critical Issues for Oncology. <i>Journal of Clinical Oncology</i> , 2012, 30, 4275-4281.	0.8	24
65	Implementation of Cancer Clinical Care Pathways: A Successful Model of Collaboration Between Payers and Providers. <i>Journal of Oncology Practice</i> , 2012, 8, e38s-e43s.	2.5	30
66	Infused Chemotherapy Use in the Elderly After Patent Expiration. <i>Journal of Oncology Practice</i> , 2012, 8, e18s-e23s.	2.5	7
67	A Way Forward on the Medically Appropriate Use of White Cell Growth Factors. <i>Journal of Clinical Oncology</i> , 2012, 30, 1584-1587.	0.8	14
68	Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare. <i>Journal of Cancer Epidemiology</i> , 2012, 2012, 1-13.	0.5	20
69	High-Cost Imaging in Elderly Patients with Stage IV Cancer: Challenges for Research, Policy, and Practice. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1113-1114.	3.0	12
70	The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 1179-1189.	0.2	16
71	A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe. <i>Journal of Oncology Pharmacy Practice</i> , 2012, 18, 57-67.	0.5	12
72	Physician response to financial incentives when choosing drugs to treat breast cancer. <i>International Journal of Health Care Finance and Economics</i> , 2012, 12, 285-302.	1.2	22
73	Scanning the horizon—Development and implementation of an early awareness system for anticancer drugs in Austria. <i>Health Policy</i> , 2012, 104, 1-11.	1.4	18
74	A framework for understanding cancer comparative effectiveness research data needs. <i>Journal of Clinical Epidemiology</i> , 2012, 65, 1150-1158.	2.4	26
75	Commonalities and differences in HTA outcomes: A comparative analysis of five countries and implications for coverage decisions. <i>Health Policy</i> , 2012, 108, 167-177.	1.4	72
76	The High Cost of Cancer Drugs and What We Can Do About It. <i>Mayo Clinic Proceedings</i> , 2012, 87, 935-943.	1.4	189
77	Bronchoscopic Intervention Obviates the Need for Continued Mechanical Ventilation in Patients with Airway Obstruction and Respiratory Failure from Inoperable Non-Small-Cell Lung Cancer. <i>Respiration</i> , 2012, 84, 55-61.	1.2	44
78	Pricing and Reimbursement in US Pharmaceutical Markets. , 2012, , .		16
79	Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma. <i>Cancer</i> , 2012, 118, 6079-6088.	2.0	28
80	The economic pressures for biosimilar drug use in cancer medicine. <i>Targeted Oncology</i> , 2012, 7, 57-67.	1.7	77

#	ARTICLE	IF	CITATIONS
81	Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 505-512.	0.8	22
82	Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012, 37, 547-552.	0.7	18
83	Operations Research and Health Care Policy. <i>Profiles in Operations Research</i> , 2013, , .	0.3	10
84	Reforming the Payment System for Medical Oncology. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 261.	3.8	14
85	Anti-vascular endothelial growth factor therapy in the era of personalized medicine. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1-12.	1.1	17
86	The person in personalised medicine. <i>European Journal of Cancer</i> , 2013, 49, 1159-1160.	1.3	30
87	Communication Challenges for Chronic Metastatic Cancer in an Era of Novel Therapeutics. <i>Qualitative Health Research</i> , 2013, 23, 863-875.	1.0	33
88	Which Is More Valuable, Longer Survival or Better Quality of Life? Israeli Oncologistsâ€™ and Family Physiciansâ€™ Attitudes Toward the Relative Value of New Cancer and Congestive Heart Failure Interventions. <i>Value in Health</i> , 2013, 16, 842-847.	0.1	12
89	Value and payment for oncology in the United States. <i>Annales Pharmaceutiques Francaises</i> , 2013, 71, 285-290.	0.4	3
90	Appraising iniparib, the PARP inhibitor that never wasâ€™ what must we learn?. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 688-696.	12.5	81
91	What Does Breast Cancer Treatment Cost and What Is It Worth?. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 829-841.	0.9	13
92	Oncologistsâ€™ and family physiciansâ€™ views on value for money of cancer and congestive heart failure care. <i>Israel Journal of Health Policy Research</i> , 2013, 2, 44.	1.4	10
93	Quality-adjusted life years in cancer: pros, cons, and alternatives. <i>European Journal of Cancer Care</i> , 2013, 22, 12-19.	0.7	7
94	Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines. <i>Leukemia Research</i> , 2013, 37, 675-680.	0.4	30
95	Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists. <i>Journal of Clinical Oncology</i> , 2013, 31, 1134-1139.	0.8	113
96	Rediscovering the Core of Public Health. <i>Annual Review of Public Health</i> , 2013, 34, 287-299.	7.6	27
97	Relevance of Health Economics in Breast Cancer Treatment: Integration of Economics in the Management of Breast Cancer at the Clinic Level. <i>Breast Care</i> , 2013, 8, 7-14.	0.8	7
98	Health Care Spending â€™ A Giant Slain or Sleeping?. <i>New England Journal of Medicine</i> , 2013, 369, 2551-2557.	13.9	42

#	ARTICLE	IF	CITATIONS
99	Informing Canada's Cancer Drug Funding Decisions with Scientific Evidence and Patient Perspectives: The Pan-Canadian Oncology Drug Review. <i>Current Oncology</i> , 2013, 20, 121-124.	0.9	33
100	Advancing Comparative Studies of Patterns of Care and Economic Outcomes in Cancer: Challenges and Opportunities. <i>Journal of the National Cancer Institute Monographs</i> , 2013, 2013, 1-6.	0.9	12
101	Initial Treatment for Newly Diagnosed Elderly Colorectal Cancer Patients: Patterns of Care in Italy and the United States. <i>Journal of the National Cancer Institute Monographs</i> , 2013, 2013, 88-98.	0.9	13
103	Out of Pocket, Out of Sight? An Unmeasured Component of the Burden of Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 252-253.	3.0	11
104	Publication Patterns of Cancer Cost-Effectiveness Studies Presented at Major Conferences. <i>Current Oncology</i> , 2013, 20, 319-325.	0.9	5
106	Documenting the Benefits and Cost Savings of a Large Multistate Cancer Pathway Program From a Payer's Perspective. <i>Journal of Oncology Practice</i> , 2013, 9, e241-e247.	2.5	33
107	Appropriateness and Right Price: An Inseparable Binomial to Improve Care and Reduce Cost. <i>Journal of Clinical Oncology</i> , 2013, 31, 2223-2223.	0.8	1
108	Practice-Changing Strategies to Deliver Affordable, High-Quality Cancer Care: Summary of an Institute of Medicine Workshop. <i>Journal of Oncology Practice</i> , 2013, 9, 54s-59s.	2.5	7
109	Cancer Drugs in the United States: <i>Justum Pretium</i> "The Just Price. <i>Journal of Clinical Oncology</i> , 2013, 31, 3600-3604.	0.8	276
110	Integrating Patient Incentives with Episode-Based Payment. <i>Forum for Health Economics and Policy</i> , 2013, 16, 123-136.	0.2	0
111	Efficient Allocation of Novel Agents in Multiple Myeloma: A Work in Progress. <i>Oncologist</i> , 2013, 18, 5-7.	1.9	6
112	BIOTECHNOLOGY INNOVATION: A LEGITIMACY-BASED VIEW. <i>International Journal of Innovation and Technology Management</i> , 2013, 10, 1350015.	0.8	3
113	The Cost of Breast Cancer Screening in the Medicare Population. <i>JAMA Internal Medicine</i> , 2013, 173, 220.	2.6	60
114	The Timing of Drug Funding Announcements Relative to Elections: A Case Study Involving Dementia Medications. <i>PLoS ONE</i> , 2013, 8, e56921.	1.1	4
115	Cost-Effectiveness Evaluation of Oncological Drugs Newly Marketed in Italy. <i>Global & Regional Health Technology Assessment</i> , 2014, 1, GRHTA.5000182.	0.2	9
116	An Ethical Framework for Pharmacy Management: Balancing Autonomy and Other Principles. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 334-338.	2.2	3
117	Obstacles to Affordable Cancer Treatments. <i>North Carolina Medical Journal</i> , 2014, 75, 257-260.	0.1	6
118	Value Considerations in the Treatment of Head and Neck Cancer: Radiation, Chemotherapy, and Supportive Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e296-e303.	1.8	9

#	ARTICLE	IF	CITATIONS
119	Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3436-3448.	0.8	201
120	Economic evaluation of therapeutic cancer vaccines and immunotherapy: A systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3415-3424.	1.4	39
121	International comparison of the factors influencing reimbursement of targeted anti-cancer drugs. <i>BMC Health Services Research</i> , 2014, 14, 595.	0.9	13
122	National Trends In Spending On And Use Of Oral Oncologics, First Quarter 2006 Through Third Quarter 2011. <i>Health Affairs</i> , 2014, 33, 1721-1727.	2.5	50
123	Survival and Lifetime Costs Associated With First-Line Bevacizumab Use in Older Patients With Metastatic Colorectal Cancer. <i>Oncologist</i> , 2014, 19, 892-899.	1.9	19
124	Toxicity and Costs of Toxicity Associated With New Cancer Drugs: International Implications. <i>Journal of Clinical Oncology</i> , 2014, 32, 3591-3592.	0.8	11
125	Specialty Medications: Traditional And Novel Tools Can Address Rising Spending On These Costly Drugs. <i>Health Affairs</i> , 2014, 33, 1736-1744.	2.5	46
126	Indication-Specific Pricing for Cancer Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1629.	3.8	107
127	Unintended Consequences of Expensive Cancer Therapeuticsâ€”The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 1225.	1.2	263
128	Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. <i>Lancet Oncology, The</i> , 2014, 15, e112-e118.	5.1	80
129	Drug waste minimization as an effective strategy of cost-containment in Oncology. <i>BMC Health Services Research</i> , 2014, 14, 57.	0.9	58
130	Improving the efficiency of cost-effectiveness analysis to inform policy decisions in the real world: lessons from the Pharmacoeconomics Research Unit at Cancer Care Ontario. <i>BMC Health Services Research</i> , 2014, 14, .	0.9	1
131	Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 719-725.	0.8	27
132	A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: sorafenib for second line renal cell cancer. <i>Cost Effectiveness and Resource Allocation</i> , 2014, 12, 12.	0.6	9
133	Rising cost of anticancer drugs in <sc>A</sc>ustralia. <i>Internal Medicine Journal</i> , 2014, 44, 458-463.	0.5	31
134	Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries. <i>Lancet Oncology, The</i> , 2014, 15, e119-e131.	5.1	124
135	Access to innovation: Is there a difference in the use of expensive anticancer drugs between French hospitals?. <i>Health Policy</i> , 2014, 116, 162-169.	1.4	6
136	Principles and Reality of Proton Therapy Treatment Allocation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 499-508.	0.4	29

#	ARTICLE	IF	CITATIONS
137	Impact of Indiscriminate Use of Pump Infusion Set (Pis) on the Cost of Chemotherapy Treatments: A Cost Minimization Study. Value in Health, 2015, 18, A818.	0.1	0
138	Polls and Policy: Signals or Substance. Journal of Clinical Oncology, 2015, 33, 819-820.	0.8	1
140	Five Policy Levers To Meet The Value Challenge In Cancer Care. Health Affairs, 2015, 34, 1563-1568.	2.5	7
143	Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis. Leukemia Research and Treatment, 2015, 2015, 1-12.	2.0	16
144	The cost of multiple sclerosis drugs in the US and the pharmaceutical industry. Neurology, 2015, 84, 2185-2192.	1.5	229
145	Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011. Journal of Clinical Oncology, 2015, 33, 2190-2196.	0.8	132
146	Five Years of Cancer Drug Approvals. JAMA Oncology, 2015, 1, 539.	3.4	271
147	Pricing in the Market for Anticancer Drugs. Journal of Economic Perspectives, 2015, 29, 139-162.	2.7	379
148	Barriers to access and use of high cost medicines: A review. Health Policy and Technology, 2015, 4, 191-214.	1.3	23
149	Challenges and Opportunities in Measuring Cancer Recurrence in the United States. Journal of the National Cancer Institute, 2015, 107, djv134-djv134.	3.0	59
150	Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs. JAMA - Journal of the American Medical Association, 2015, 314, 2503.	3.8	66
151	Making personalized medicine more affordable. Annals of the New York Academy of Sciences, 2015, 1346, 81-89.	1.8	17
152	Treating Age-Related Macular Degeneration: Comparing The Use Of Two Drugs Among Medicare And Veterans Affairs Populations. Health Affairs, 2015, 34, 229-238.	2.5	11
153	Patients and Physicians Can Discuss Costs of Cancer Treatment in the Clinic. Journal of Oncology Practice, 2015, 11, 308-312.	2.5	59
154	A Time-Trend Economic Analysis of Cancer Drug Trials. Oncologist, 2015, 20, 729-736.	1.9	35
155	Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea. Health Policy, 2015, 119, 577-587.	1.4	17
156	Can Money Really Be No Object When Cancer Care Is the Subject?. Journal of Clinical Oncology, 2015, 33, 1093-1094.	0.8	21
157	Expanding the Scope of the National Practice Oncology Benchmark Would Be a Critical Source for Understanding Outpatient Oncology Practice Costs and Profits in a Time of Change. Journal of Oncology Practice, 2015, 11, e95-e97.	2.5	3

#	ARTICLE	IF	CITATIONS
158	How State And Federal Policies As Well As Advances In Genome Science Contribute To The High Cost Of Cancer Drugs. Health Affairs, 2015, 34, 571-575.	2.5	17
159	Cost Considerations in the Evaluation and Treatment of Colorectal Cancer. Current Treatment Options in Oncology, 2015, 16, 41.	1.3	8
160	Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 3727-3732.	0.8	86
162	Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Leukemia and Lymphoma, 2015, 56, 2315-2325.	0.6	19
163	Population-Based Trends in Systemic Therapy Use and Cost for Cancer Patients in the Last Year of Life. Current Oncology, 2016, 23, 32-41.	0.9	19
164	Value, Access, and Cost of Cancer Care Delivery at Academic Cancer Centers. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 837-847.	2.3	29
165	The changing landscape of biosimilars in rheumatology. Annals of the Rheumatic Diseases, 2016, 75, 974-982.	0.5	160
166	Public referendum on drug prices in the US: will it bring relief?. BMJ, The, 2016, 355, i5657.	3.0	7
167	A View from the Bridge: Health Economic Evaluation "A Value-Based Framework?. Health Economics (United Kingdom), 2016, 25, 1499-1502.	0.8	10
168	A Touchy Subject: Can Physicians Improve Value by Discussing Costs and Clinical Benefits With Patients?. Oncologist, 2016, 21, 1157-1160.	1.9	12
169	Me, Too. Journal of Global Oncology, 2016, 2, 99-104.	0.5	13
170	Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases. International Journal of Radiation Oncology Biology Physics, 2016, 95, 663-672.	0.4	29
171	ReCAP: Hospitalizations in Older Adults With Advanced Cancer: The Role of Chemotherapy. Journal of Oncology Practice, 2016, 12, 151-152.	2.5	25
172	Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure. Health Affairs, 2016, 35, 805-812.	2.5	62
173	Adjusting for Drug Wastage in Economic Evaluations of New Therapies for Hematologic Malignancies: A Systematic Review. Journal of Oncology Practice, 2016, 12, e369-e379.	2.5	30
174	Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014. JAMA Oncology, 2016, 2, 960.	3.4	94
175	The right amount of chemotherapy in non-curable disease: Insights from health economics. Journal of Cancer Policy, 2016, 10, 30-35.	0.6	0
176	Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2016, 34, 4323-4328.	0.8	97

#	ARTICLE	IF	CITATIONS
177	Physician-Driven Variation in Nonrecommended Services Among Older Adults Diagnosed With Cancer. <i>JAMA Internal Medicine</i> , 2016, 176, 1541.	2.6	44
179	Economics of ramucirumab for metastatic colorectal cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 733-745.	0.7	3
180	Trends in annual drug expenditure â€” a 16 year perspective of a public healthcare maintenance organization. <i>Israel Journal of Health Policy Research</i> , 2016, 5, 37.	1.4	4
182	Cancer care cost trends in the United States: 1998 to 2012. <i>Cancer</i> , 2016, 122, 1078-1084.	2.0	22
183	Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data. <i>Medical Care</i> , 2016, 54, 343-349.	1.1	23
184	Reimbursing Wisely? CMS's Trial of Medicare Part B Drug Payment Reform. <i>New England Journal of Medicine</i> , 2016, 374, 2101-2105.	13.9	21
185	The 5000% case: a glimpse into the financial issue of lung cancer treatment. <i>European Respiratory Journal</i> , 2016, 47, 1331-1333.	3.1	2
186	Costos directos de la atención del cáncer de mama en Colombia. <i>Revista Colombiana De Cancerología</i> , 2016, 20, 52-60.	0.0	11
187	ReCAP: Cost Differential of Chemotherapy for Solid Tumors. <i>Journal of Oncology Practice</i> , 2016, 12, 251-251.	2.5	12
188	Financial Toxicity of Cancer Care: It's Time to Intervene. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv370.	3.0	324
189	Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 375-380.	0.8	56
190	Cancer Care in Countries and Societies in Transition. , 2016, , .		8
191	Propaganda or the cost of innovation? Challenging the high price of new drugs. <i>BMJ</i> , The, 2016, 352, i1284.	3.0	17
192	Trends in the Treatment of Metastatic Colon and Rectal Cancer in Elderly Patients. <i>Medical Care</i> , 2016, 54, 490-497.	1.1	52
193	Cost-Utility Analysis of Cancer Prevention, Treatment, and Control. <i>American Journal of Preventive Medicine</i> , 2016, 50, 241-248.	1.6	48
194	Antioxidant, Anti-inflammatory, and Genomic Stability Enhancement Effects of Zinc-l-carnosine: A Potential Cancer Chemopreventive Agent?. <i>Nutrition and Cancer</i> , 2017, 69, 201-210.	0.9	24
195	Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. <i>Journal of Clinical Oncology</i> , 2017, 35, 166-174.	0.8	131
196	Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. <i>Clinical Cancer Research</i> , 2017, 23, 1407-1413.	3.2	11

#	ARTICLE	IF	CITATIONS
197	Drivers of poor medical care. <i>Lancet, The</i> , 2017, 390, 178-190.	6.3	181
198	Cost-Effectiveness of Immune Checkpoint Inhibition in <i>BRAF</i> Wild-Type Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1194-1202.	0.8	89
199	Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. <i>Clinical Cancer Research</i> , 2017, 23, 1414-1421.	3.2	29
200	Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer. <i>Annals of Oncology</i> , 2017, 28, 1825-1831.	0.6	47
201	Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. <i>Cancer</i> , 2017, 123, 3763-3771.	2.0	25
202	How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?. <i>Npj Breast Cancer</i> , 2017, 3, 20.	2.3	33
203	Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending. <i>JAMA Internal Medicine</i> , 2017, 177, 1185.	2.6	54
204	Socioeconomic disparities, financial toxicity, and opportunities for enhanced system efficiencies for patients with cancer. <i>Journal of Surgical Oncology</i> , 2017, 115, 250-256.	0.8	39
205	The high price of anticancer drugs: origins, implications, barriers, solutions. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 381-390.	12.5	289
206	Follow-up care of cancer survivors: challenges and solutions. <i>Lancet Oncology, The</i> , 2017, 18, e19-e29.	5.1	146
207	A Quininiib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab. <i>Journal of Biological Chemistry</i> , 2017, 292, 3552-3567.	1.6	19
208	Adoption of Sorafenib for the Treatment of Advanced-Stage Hepatocellular Carcinoma in Oncology Practices in the United States. <i>Liver Cancer</i> , 2017, 6, 216-226.	4.2	17
209	Innovative payer engagement strategies: will the convergence lead to better value creation in personalized medicine?. <i>EPMA Journal</i> , 2017, 8, 5-15.	3.3	12
210	Cost of Care for the Initial Management of Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2017, 130, 1269-1275.	1.2	36
211	A Systematic Review of the Effect of Cancer Treatment on Work Productivity of Patients and Caregivers. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 136-162.	0.5	47
213	Low-value practices in oncology contributing to financial toxicity. <i>Ecancelmedicalscience</i> , 2017, 11, 727.	0.6	19
214	Comparing the Approval and Coverage Decisions of New Oncology Drugs in the United States and Other Selected Countries. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 247-254.	0.5	18
215	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 3240-3261.	0.8	454

#	ARTICLE	IF	CITATIONS
216	Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3306-3314.	0.8	35
218	Medical Care Costs Associated With Cancer in Integrated Delivery Systems. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 402-410.	2.3	53
219	Translational Research and Innovation in Human and Health Science. <i>Annals of Medicine</i> , 2018, 50, S10-S170.	1.5	3
220	The financial burden and distress of patients with cancer: Understanding and stepping up action on the financial toxicity of cancer treatment. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 153-165.	157.7	542
221	Proportion of patients with cancer among high-cost Medicare beneficiaries: Who they are and what drives their spending. <i>Healthcare</i> , 2018, 6, 46-51.	0.6	5
222	Oncologists'™ Views on Using Value to Guide Cancer Treatment Decisions. <i>Value in Health</i> , 2018, 21, 931-937.	0.1	4
223	Trends in antineoplastic receipt after medicare payment reform: Implications for future oncology payment design. <i>Journal of Cancer Policy</i> , 2018, 17, 51-58.	0.6	2
224	Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 424-432.	0.5	15
225	Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1700-1709.	0.6	28
226	The Local Influence of Pioneer Investigators on Technology Adoption: Evidence from New Cancer Drugs. <i>Review of Economics and Statistics</i> , 2018, 100, 29-44.	2.3	28
227	Spending on Antineoplastic Agents in the United States, 2011 to 2016. <i>Journal of Oncology Practice</i> , 2018, 14, e683-e691.	2.5	13
228	The role of pharmacology in anticancer drug development. <i>ADMET and DMPK</i> , 2018, 6, 4.	1.1	0
229	Trajectories of Injectable Cancer Drug Costs After Launch in the United States. <i>Journal of Clinical Oncology</i> , 2018, 36, 319-325.	0.8	80
230	Cost, Value, and Financial Hardship in Cancer Care: Implications for Pediatric Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 850-860.	1.8	16
231	Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3307-3314.	0.8	37
232	Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time. <i>Journal of Oncology Practice</i> , 2018, 14, e280-e294.	2.5	69
233	Medical Financial Hardship among Cancer Survivors in the United States: What Do We Know? What Do We Need to Know?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1389-1397.	1.1	68
234	Accelerating anticancer drug development – opportunities and trade-offs. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 777-786.	12.5	52

#	ARTICLE	IF	CITATIONS
235	Financial toxicity and implications for cancer care in the era of molecular and immune therapies. <i>Annals of Translational Medicine</i> , 2018, 6, 166-166.	0.7	126
236	Therapies Out of Reach: Anticancer Drugs and Global Trade Regimes. <i>Science, Technology and Society</i> , 2018, 23, 371-387.	1.1	1
237	Patient assistance programs: a valuable, yet imperfect, way to ease the financial toxicity of cancer care. <i>Seminars in Hematology</i> , 2018, 55, 185-188.	1.8	27
238	Design, Synthesis and Anticancer Evaluation of Oxa/Thiadiazolyhydrzones of Barbituric and Thiobarbituric Acid: A Collective In Vitro and In Silico Approach. <i>ChemistrySelect</i> , 2018, 3, 7060-7065.	0.7	11
239	Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues. <i>Pharmacoeconomics</i> , 2018, 36, 1395-1405.	1.7	35
240	Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia—the Burden of Novelty. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 237-243.	1.2	16
241	Survival impact and toxicity of metformin in head and neck cancer: An analysis of the SEER-Medicare dataset. <i>Oral Oncology</i> , 2018, 84, 12-19.	0.8	17
242	Trade-offs, fairness, and funding for cancer drugs: key findings from a deliberative public engagement event in British Columbia, Canada. <i>BMC Health Services Research</i> , 2018, 18, 339.	0.9	16
243	Recent Advances and Perspectives in Cancer Drug Design. <i>Anais Da Academia Brasileira De Ciencias</i> , 2018, 90, 1233-1250.	0.3	38
244	Access to High Cost Medicines: An Overview. , 2018, , 1-10.		0
245	Synthesis, docking and anticancer activity of azo-linked hybrids of 1,3,4-thia/oxadiazoles with cyclic imides. <i>Molecular Diversity</i> , 2018, 22, 827-840.	2.1	10
246	Synthesis, Anticancer and Antimicrobial Evaluation of New (<i>E</i>)<i>N</i>-Benzylidene-(2-ethylpyridin-4-yl)-methylthiazole-5-carbohydrazides. <i>ChemistrySelect</i> , 2019, 4, 8993-8997.		3
247	Modeling dynamics and alternative treatment strategies in acute promyelocytic leukemia. <i>PLoS ONE</i> , 2019, 14, e0221011.	1.1	3
249	Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs. <i>BMC Public Health</i> , 2019, 19, 977.	1.2	11
250	Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017. <i>Value in Health</i> , 2019, 22, 1387-1395.	0.1	8
251	Study protocol: Randomized controlled trial of web-based decision support tools for high-risk women and healthcare providers to increase breast cancer chemoprevention. <i>Contemporary Clinical Trials Communications</i> , 2019, 16, 100433.	0.5	9
252	Current and Future Oncology Management in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 272-281.	0.5	15
254	When oncologic treatment options outpace the existing evidence: Contributing factors and a path forward. <i>Journal of Cancer Policy</i> , 2019, 20, 100188.	0.6	2

#	ARTICLE	IF	CITATIONS
255	Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 374-387.	1.8	19
256	An Insurer's Program To Incentivize Generic Oncology Drugs Did Not Alter Treatment Patterns Or Spending On Care. Health Affairs, 2019, 38, 812-819.	2.5	4
257	Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach. Integrative Cancer Therapies, 2019, 18, 153473541982709.	0.8	2
258	The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care. International Journal of Radiation Oncology Biology Physics, 2019, 104, 724-733.	0.4	47
259	Minimizing the burden of cancer in the United States: Goals for a high-performing health care system. Ca-A Cancer Journal for Clinicians, 2019, 69, 166-183.	157.7	69
260	If Research Libraries and Funders Finance Open Access: Moving Beyond Subscriptions and APCs. College and Research Libraries, 2019, 80, 340-355.	0.2	10
261	Financial Toxicity and Cancer Therapy. Hematology/Oncology Clinics of North America, 2019, 33, 1117-1128.	0.9	16
262	Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer. JCO Clinical Cancer Informatics, 2019, 3, 1-10.	1.0	50
263	Re: Gong et al.: Comparison of United States and international ophthalmic drug pricing		

#	ARTICLE	IF	CITATIONS
273	Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration. <i>Cancer</i> , 2020, 126, 4390-4399.	2.0	19
274	The Changing Health Insurance Coverage Landscape in the United States. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e264-e274.	1.8	4
275	Toward affordable cancer drugs: Do we need firmer price negotiation, me-too drugs, or a biosimilar silver bullet?. <i>Seminars in Oncology</i> , 2020, 47, 353-354.	0.8	0
276	Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US. <i>Social Science and Medicine</i> , 2020, 258, 113042.	1.8	28
277	An Analysis of 1-Year Charges for Head and Neck Cancer: Targets for Value-Based Interventions. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 546-553.	1.1	4
278	Medical Care Costs Associated with Cancer Survivorship in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1304-1312.	1.1	294
279	Design and Ultrasound Assisted Synthesis of Novel 1,3,4-Oxadiazole Drugs for Anti-Cancer Activity. <i>ChemistrySelect</i> , 2020, 5, 3347-3354.	0.7	13
280	Pharmaceutical Price and Spending Controls in France: Lessons for the United States. <i>International Journal of Health Services</i> , 2020, 50, 156-165.	1.2	16
281	Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice. <i>Oncologist</i> , 2020, 25, 46-54.	1.9	7
282	The Accuracy and Usefulness of the National Comprehensive Cancer Network Evidence Blocks Affordability Rating. <i>Pharmacoeconomics</i> , 2020, 38, 737-745.	1.7	5
283	Commentary on Hsiue et al: Cost savings and data limitations of new cancer drug studies. <i>Clinical Trials</i> , 2020, 17, 126-128.	0.7	1
284	The long-term effects of cancer survivorship on household assets. <i>Health Economics Review</i> , 2020, 10, 2.	0.8	18
285	Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead. <i>Value in Health</i> , 2020, 23, 421-424.	0.1	5
286	Three-Year Results of a Prospective Statewide Insurance Coverage Pilot for Proton Therapy: Stakeholder Collaboration Improves Patient Access to Care. <i>JCO Oncology Practice</i> , 2020, 16, e966-e976.	1.4	9
287	Time to add screening for financial hardship as a quality measure?. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 100-106.	157.7	26
288	Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma. <i>JCO Oncology Practice</i> , 2021, 17, e266-e277.	1.4	12
289	Financial Toxicity and Cancer Care #409. <i>Journal of Palliative Medicine</i> , 2021, 24, 453-454.	0.6	6
290	Common Pharmaceutical Price and Cost Controls in the United Kingdom, France, and Germany: Lessons for the United States. <i>International Journal of Health Services</i> , 2021, 51, 379-391.	1.2	9

#	ARTICLE	IF	CITATIONS
291	The Financial Burden of Cancer on Families in the United States. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3790.	1.2	4
292	Characterization of the Early Years of Bevacizumab Use for First-Line Treatment of Ovarian Cancer in the United States. <i>JCO Oncology Practice</i> , 2021, 17, OP.20.00918.	1.4	2
293	Triazole based isatin derivatives as potential inhibitor of key cancer promoting kinases- insight from electronic structure, docking and molecular dynamics simulations. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 107, 107944.	1.3	4
294	Flow synthesis kinetics for lomustine, an anti-cancer active pharmaceutical ingredient. <i>Reaction Chemistry and Engineering</i> , 2021, 6, 1819-1828.	1.9	11
295	Association of Neighborhood Deprivation Index With Success in Cancer Care Crowdfunding. <i>JAMA Network Open</i> , 2020, 3, e2026946.	2.8	25
296	Improving the Efficiency of Cost-effectiveness Analysis to Inform Policy Decisions in the Real World: Lessons from the Pharmacoeconomics Research Unit at Cancer Care Ontario. <i>Profiles in Operations Research</i> , 2013, , 399-416.	0.3	1
297	Economics of Bladder Cancer Diagnosis and Surveillance. , 2011, , 121-137.		1
298	Allocating Cancer-Directed Expenditures: Tensions Between Prevention, Early Detection and Treatment is Unnecessary. <i>Recent Results in Cancer Research</i> , 2010, 188, 1-9.	1.8	1
299	Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid Leukemia. <i>JCO Oncology Practice</i> , 2021, 17, e517-e525.	1.4	4
300	Addressing Barriers to Uptake of Breast Cancer Chemoprevention for Patients and Providers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e50-e58.	1.8	21
301	Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e75-e80.	1.8	19
302	Incidence and mortality of kidney cancer and its relationship with HDI (Human Development Index) in the world in 2012. <i>Medicine and Pharmacy Reports</i> , 2017, 90, 286-293.	0.2	13
303	Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada. <i>Oncologist</i> , 2020, 25, e130-e137.	1.9	19
306	The Impact of Biosimilars in Supportive Care in Cancer. <i>European Oncology and Haematology</i> , 2018, 14, 20.	0.0	6
307	Health Technology Assessment, 2014, 2, 68-78.		
308	Drug delivery from engineered organisms and nanocarriers as monitored by multimodal imaging technologies. <i>AIMS Bioengineering</i> , 2017, 4, 198-222.	0.6	4
309	Value-based medicine in oncology: the importance of perspective in the emerging value frameworks. <i>Clinics</i> , 2018, 73, e470s.	0.6	9
310	Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System. <i>Frontiers in Pharmacology</i> , 2021, 12, 754390.	1.6	3

#	ARTICLE	IF	CITATIONS
311	Spending and Utilization on Drugs Prescribed by Otolaryngologists to Medicare Beneficiaries, 2013 to 2017. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2021, , 000348942110504.	0.6	0
312	The Economics of the Hematopoietic Growth Factors. <i>Cancer Treatment and Research</i> , 2010, 157, 403-418.	0.2	0
313	Health Economics and Cancer Survivorship. , 2011, , 299-327.		0
314	How Will Health Care Reform Change the Way We Practice Medicine?. , 2011, , 147-164.		0
315	A InduÃ§Ã£o da Procura Mediante a PromoÃ§Ã£o da Chance TerapÃ©utica - A ProblemÃ¡tica dos Ganhos de Chance Promovidos pela RecomendaÃ§Ã£o MÃ©dica em Tratamentos sem Efeito DiscernÃvel nos Pacientes. <i>Economic Analysis of Law Review</i> , 2011, 2, 352-403.	0.0	0
316	The Efficacy and Cost of Biological Targeted Agents in Oncology. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
317	Opportunities for Oncology in the Patient Protection and Affordable Care Act. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 436-440.	1.8	2
319	Cancer Treatment: the Cost Factor. <i>West Indian Medical Journal</i> , 2014, 63, 766-70.	0.4	0
320	A Drug Cost Estimation Model and its Determinant Factors for Breast Cancer Patient Hospitalized in Indonesia. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
321	Restraining High and Rising Cancer Drug Prices: Need for Accelerating R&D Productivity and Aligning Prices with Value. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
322	Challenges in Obtaining Effective Access to Prescribed Drugs and Protection Against Financial Disruption: Addressing Barriers to Cancer Care in Ontario. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
323	The Unaccounted Insurance Value of Medical Innovation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
324	Financial Hardship. , 2018, , 111-125.		2
326	Therapy of Cancer and Retroviral Diseases. , 2019, , 65-158.		1
327	The Economics of Rectal Cancer Care: Considerations in Interpretation of the Literature. , 2019, , 613-625.		0
328	Geographic Variation in Medical Neighborhoods for Breast Cancer Care: Diagnosis and Beyond. <i>Energy Balance and Cancer</i> , 2019, , 331-357.	0.2	1
329	Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 252-259.	0.9	0
330	Economic challenges of oncological diseasesâ€™ pharmacotherapy. <i>Farmakoekonomika</i> , 2020, 13, 64-70.	0.4	1

#	ARTICLE	IF	CITATIONS
331	German Pharmaceutical Pricing: Lessons for the United States. <i>International Journal of Health Services</i> , 2022, 52, 146-158.	1.2	8
333	How patient cost-sharing trends affect adherence and outcomes: a literature review. <i>P and T</i> , 2012, 37, 45-55.	1.0	122
335	Emerging trends in cancer care: health plans' and pharmacy benefit managers' perspectives on changing care models. <i>American Health and Drug Benefits</i> , 2012, 5, 242-53.	0.5	2
336	Financial toxicity, Part I: a new name for a growing problem. <i>Oncology</i> , 2013, 27, 80-1, 149.	0.4	177
337	It's time to have 'the talk': cost communication and patient-centered care. <i>Oncology</i> , 2014, 28, 479-80.	0.4	9
338	The Cost of Oncology Drugs: A Pharmacy Perspective, Part 2. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2016, 33, 35-39.	0.6	0
339	The Cost of Oncology Drugs: A Pharmacy Perspective, Part I. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2016, 33, 22S-25S.	0.6	1
340	Dual HER2-Targeting in the Adjuvant Setting: Where We Have Been and Where We Are Going. <i>Oncology</i> , 2018, 32, 483-7.	0.4	2
341	Association Between Clinical Value and Financial Cost of Cancer Treatments: A Cross-Sectional Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1349-1353.	2.3	0
342	Financial toxicity in cancer care: origins, impact, and solutions. <i>Translational Behavioral Medicine</i> , 2021, 11, 2043-2054.	1.2	50
343	Association Between Clinical Value and Financial Cost of Cancer Treatments: A Cross-Sectional Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1349-1353.	2.3	9
344	German Pharmaceutical Pricing: Lessons for the U.S.. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
345	First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 788569.	1.6	17
346	Multicriteria decision analysis in health care decision in oncology: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 365-380.	0.7	3
348	Multiple Criteria Decision Analysis (MCDA) for evaluating cancer treatments in hospital-based health technology assessment: The Paraconsistent Value Framework. <i>PLoS ONE</i> , 2022, 17, e0268584.	1.1	5
349	Trends and costs of stereotactic body radiation therapy in metastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2022, .	0.6	4
350	Assessing U.S. Pharmaceutical Policy and Pricing Reform Legislation in Light of European Price and Cost Control Strategies. <i>Journal of Health Politics, Policy and Law</i> , 2022, , .	0.9	2
352	Financial Toxicity and Its Association With Prostate and Colon Cancer Screening. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 981-988.	2.3	5

#	ARTICLE	IF	CITATIONS
353	Oncology biosimilars: New developments and future directions. <i>Cancer Reports</i> , 2022, 5, .	0.6	6
354	Precision Medicine and Novel Therapeutic Strategies in Detection and Treatment of Cancer: Highlights from the 58th IACR Annual Conference. <i>Cancers</i> , 2022, 14, 6213.	1.7	0
355	The Dynamics of Financial Toxicity in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, 266-272.	0.2	6
356	Modelos de impacto presupuestario. Una nueva herramienta de evaluación para drogas de alto costo en oncología. , 2015, 20, .		0
357	Evaluation of the association between health insurance status and healthcare utilization and expenditures among adult cancer survivors in the United States. <i>Research in Social and Administrative Pharmacy</i> , 2023, 19, 821-829.	1.5	2
358	Cancer Drug Prices in the US: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
363	Economic Evaluation in Health Services Research. , 2023, , 187-198.		0